PRESS RELEASE: Sydney Digital Health Platform OnTracka Secures US NIH Footprint to Power Phase 2 Obesity Trial Infrastructure

SYDNEY, NSW — 1 August 2026

Australian digital health infrastructure platform OnTracka has solidified its position in the global enterprise sector, securing contracts to provide the core digital monitoring architecture for multiple high-profile clinical trials in the United States funded by National Institutes of Health (NIH) grants.

In its latest global deployment launching in two weeks, OnTracka’s enterprise software will serve as the primary monitoring infrastructure for a US Phase 2, randomized, double-masked clinical trial evaluating a novel, protocol-led treatment pathway for adults with obesity. Amidst a global healthcare market heavily reshaped by the commercial boom of injectable GLP-1 medicines, the NIH-backed study aims to validate alternative, evidence-based therapeutic avenues.

The Sydney-founded company, which specializes in decentralized clinical trials and real-world evidence (RWD/RWE) capture, has recorded over 13 million clinical data points while maintaining an industry-leading patient retention rate above 85%. This exceptional compliance metric has driven the platform’s adoption by top-tier international research institutions seeking rigorous data protocol standards.

OnTracka operates strictly as a high-barrier, enterprise-grade B2B infrastructure partner for global clinical trial sponsors, researchers, and healthcare institutions. The platform was originally founded by forensic social worker Chad Walkaden following his survival of Stage IV cancer at Westmead Hospital.

For more information, visit the corporate portal at https://ontracka.com